Rapid progression of antiviral treatments of chronic hepatitis C virus infection.
Authors: Pol S, Corouge M, Mallet V, Sogni P
Abstract
The treatment of hepatitis C virus (HCV) infection with pegylated interferon alfa and ribavirin leads to a sustained virologic response in around 50% of patients with HCV genotype 1, 65% with HCV genotype 4, 75% with HCV genotype 3 and around 80% with HCV genotype 2. A better understanding of the HCV life-cycle recently resulted in the development of several potential direct-acting antiviral drugs (DAAs) targeting viral proteins (NS3/4A protease inhibitors, NS5B nucleos(t)idic and non nucleos(t)idic polymerase inhibitors, NS5A replication complex inhibi...
Source: Minerva Gastroenterologica e Dietologica - November 18, 2015 Category: Gastroenterology Tags: Minerva Gastroenterol Dietol Source Type: research
Serum WFA+‐M2BP is a non‐invasive liver fibrosis marker that can predict the efficacy of direct‐acting anti‐viral‐based triple therapy for chronic hepatitis C
ConclusionSerum WFA+‐M2BP is a non‐invasive liver fibrosis marker useful for predicting the efficacy of DAA‐based triple therapy for chronic hepatitis C patients. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - October 26, 2015 Category: Drugs & Pharmacology Authors: K. Ura, N. Furusyo, E. Ogawa, T. Hayashi, H. Mukae, M. Shimizu, K. Toyoda, M. Murata, J. Hayashi Tags: Original Article Source Type: research
Analisis de Costo Efectividad y Costo Utilidad del uso de Daclatasvir+Asunaprevir en el Tratamiento de Pacientes Con Hepatitis C en Colombia, Desde La Perspectiva Del Tercer Pagado
Analizar la relación de costo efectividad del uso de daclatasvir+asunaprevir frente a peginterferón alfa+Ribaivirina más telaprevir o boceprevir para el tratamiento de hepatitis C en Colombia (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: RD Marrugo Figueroa, ME Romero Prada, G Acero Acero, PA Alfonso Quiñones Source Type: research
Simeprevir Plus Peginterferon/Ribavirin Cost-Effectiveness Analysis for the treatment of Chronic Genotype 1 Hepatitis C in Colombia
To assess the cost-effectiveness of simeprevir (SMV) plus peginterferon/ribavirin (PR) versus triple therapy regimens of boceprevir (BOC)/PR and telaprevir (TVR)/PR and PR dual therapy in treatment-naïve and treatment-experienced patients, chronically infected with hepatitis C virus (HCV) genotype 1, in Colombia. (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: JG Ariza, A Taborda, V Naciben, M Heibeck, KY Westerhout Source Type: research
Reliability of Manufacturers’ Budget Impact Estimates for Chronic Hcv Gt1 Drugs in Poland
To compare the total value of payer’s expenditures on Victrelis (boceprevir) and Incivo (telaprevir) in patients with chronic HCV GT1 estimated in the manufacturers’ Budget Impact Analyses (BIAs) submitted with the reimbursement applications to AOTMiT and actual expenditures of the National Health Fund (NHF). (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: T Iwanczuk, S Zawodnik, T Tatara, A Sliwczynski, M Brzozowska Source Type: research
Cost-Effectiveness of Simeprevir Vs. Telaprevir for The Triple Therapy of Hepatitis C In Kazakhstan
Hepatitis C Virus(HCV) is a growing health problem in the world. The aim of this study is to estimate a cost-effectiveness of a triple therapy(TT) with simeprevir compared to a TT with telaprevir for the previously treated with double therapy HCV patients in Kazakhstan. (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: C Bektur, T Nurgozhin, D Abdukhakimova Source Type: research
Medical Resource Utilisation of Australian Patients With Genotype 1 Chronic Hepatitis C: A Retrospective Observational Study
To understand medical resource utilisation (MRU) of Australian patients with genotype 1 chronic hepatitis C (GT1 CHC) including those receiving current standard of care treatment (telaprevir or boceprevir with pegylated interferon and ribavirin). (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: H McElroy, S Roberts, A Thompson, P Angus, SJ McKenna, E Warren, S Musgrave Source Type: research
HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients
The addition of the oral hepatitis C virus (HCV) protease inhibitors boceprevir (BOC) or telaprevir (TVR) to pegylated interferon (PegIFN) plus ribavirin (RBV) therapy has remarkably improved HCV treatment outcome in HIV/HCV coinfected patients [1–4]. However, treatments for chronic hepatitis C are evolving at a rapid pace and first generation HCV protease inhibitors, BOC and TVR in combination with PegIFN/RBV are no longer recommended in some countries. Nevertheless, costs directly affects access to second generation direct acting antiviral (DAA) drugs for HCV treatment around the world. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - October 19, 2015 Category: Virology Authors: D. Salmon, F. Bani-sadr, C. Gilbert, E. Rosenthal, Ma. Valantin, A. Simon, D. Neau, P. Morlat, Ma Loko, L. wittkop, F. dabis, for the ANRS CO13HEPAVIH study group Tags: Short Communication Source Type: research
Efficacy and Safety of Telaprevir, Pegylated Interferon α-2b and Ribavirin Triple Therapy in Japanese Patients Infected with Hepatitis C Virus Genotype 1b.
Conclusion For TVR-based triple therapy, continuation of therapy is the most important predictor of SVR. Patients who are likely intolerant of standard-dose TVR should receive reduced initial doses of TVR to avoid discontinuation of therapy.
PMID: 26466688 [PubMed - in process] (Source: Internal Medicine)
Source: Internal Medicine - October 17, 2015 Category: Internal Medicine Tags: Intern Med Source Type: research
Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals.
Abstract
About 130-170 million people are infected with the hepatitis C virus (HCV) worldwide and more than 350000 people die each year of HCV-related liver diseases. The combination of pegylated interferon (Peg-IFN) and ribavirin (RBV) was recommended as the treatment of choice for chronic hepatitis C for nearly a decade. In 2011 the directly acting antivirals (DAA) HCV NS3/4A protease inhibitors, telaprevir and boceprevir, were approved to treat HCV-genotype-1 infection, each in triple combination with Peg-IFN and RBV. These treatments allowed higher rates of SVR than the double Peg-IFN + RBV, but the lo...
Source: World Journal of Gastroenterology : WJG - October 14, 2015 Category: Gastroenterology Authors: Coppola N, Pisaturo M, Zampino R, Macera M, Sagnelli C, Sagnelli E Tags: World J Gastroenterol Source Type: research
Impact of new treatment options for hepatitis C virus infection in liver transplantation.
Abstract
Liver transplant candidates and recipients with hepatitis C virus (HCV)-related liver disease greatly benefit from an effective antiviral therapy. The achievement of a sustained virological response before transplantation can prevent the recurrence of post-transplant HCV disease that occurs universally and correlates with enhanced progression to graft cirrhosis. Previous standard-of-care regimens (e.g., pegylated-interferon plus ribavirin with or without first generation protease inhibitors, boceprevir and telaprevir) displayed suboptimal results and poor tolerance in liver transplant recipients. ...
Source: World Journal of Gastroenterology : WJG - October 14, 2015 Category: Gastroenterology Authors: Righi E, Londero A, Carnelutti A, Baccarani U, Bassetti M Tags: World J Gastroenterol Source Type: research
Pulmonary sarcoidosis in the context of a telaprevir-based triple therapy for hepatitis C
Publication date: Available online 5 October 2015 Source:Revista Portuguesa de Pneumologia (English Edition) Author(s): D. Pérez Parente, M. Suárez Santamaría, S. Suárez Ordóñez, L.E. Morano Amado (Source: Revista Portuguesa de Pneumologia)
Source: Revista Portuguesa de Pneumologia - October 6, 2015 Category: Respiratory Medicine Source Type: research
Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation‐Case report‐
This article is protected by copyright. All rights reserved. (Source: Hepatology Research)
Source: Hepatology Research - October 6, 2015 Category: Internal Medicine Authors: Tomokazu Kawaoka, Michio Imamura, Kei Morio, Yuki Nakamura, Masataka Tsuge, C. Nelson Hayes, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Kouhei Ishiyama, Kentaro Ide, Hirotaka Tashiro, Hideki Ohdan, Kazuaki Chayama Tags: Case Report Source Type: research
Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents
In this study, we present outcomes from our urban, primary care-based HCV treatment program in patients treated with telaprevir or boceprevir in combination with pegylated-interferon and ribavirin (“triple therapy”).
Methods: We collected data from 126 consecutive patients with genotype 1 HCV monoinfection seen in our treatment program (2011–2013). Among the 40 who initiated treatment, we analyzed factors associated with achieving a sustained viral response (SVR).
Results: During the study period, 40 patients initiated triple therapy (32%), 80% with recent or past substance use disorders. Patients initiating treatmen...
Source: Journal of Addiction Medicine - October 1, 2015 Category: Addiction Tags: Original Research Source Type: research
Cutaneous Eruption due to Telaprevir
We report a 53-year-old patient with cirrhosis due to HCV who started the classic treatment associated with telaprevir. In the ninth week, he presented a severe rash that required the interruption of this drug. We emphasize the importance of early recognition and appropriate management of adverse skin reaction.Case Rep Dermatol 2015;7:253-262 (Source: Case Reports in Dermatology)
Source: Case Reports in Dermatology - September 29, 2015 Category: Dermatology Source Type: research
